How did COYA's Q4 earnings surprise impact its annual performance?

Coya Therapeutics' (NASDAQ: COYA) Q4 earnings surprise had a significant impact on its annual performance, although the direct effect is not readily quantifiable due to the lack of disclosed quarterly net income data. However, we can infer the following:

1. **Positive Earnings Surprise**: Coya Therapeutics reported an earnings per share (EPS) of ($0.26) for the quarter, surpassing analysts' consensus estimates of ($0.41) by $0.15. This indicates a positive earnings surprise, which is generally viewed favorably by the market.
2. **Stock Performance**: Despite the positive earnings surprise, shares of COYA traded down $0.01 during trading on Friday, reaching $7.21. This suggests that factors other than the earnings surprise may have influenced investor sentiment.
3. **Analyst Ratings and Price Targets**: Several research firms, including Chardan Capital and HC Wainwright, have reaffirmed a "buy" rating on COYA, with price targets ranging from $14.00 to $18.00. These ratings and targets suggest that analysts are optimistic about COYA's future performance, potentially driven by the company's positive earnings surprise.
4. **Annual Performance Impact**: While the direct impact of the Q4 earnings surprise on COYA's annual performance is not provided, it is reasonable to assume that the positive surprise could have contributed to a stronger annual performance, particularly if it indicates improved operational efficiency or strategic initiatives are gaining traction.

In conclusion, COYA's Q4 earnings surprise of exceeding expectations by $0.15 could have had a positive influence on its annual performance, although the exact magnitude of this impact is not quantifiable from the available data. The company's positive earnings surprise and the optimistic analyst ratings suggest that COYA is well-positioned for future growth.